vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). ROGERS CORP runs the higher net margin — 2.2% vs 1.6%, a 0.6% gap on every dollar of revenue. On growth, ROGERS CORP posted the faster year-over-year revenue change (5.2% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -3.3%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
PCRX vs ROG — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $200.5M |
| Net Profit | $2.9M | $4.5M |
| Gross Margin | — | 32.2% |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | 2.2% |
| Revenue YoY | 5.0% | 5.2% |
| Net Profit YoY | — | 421.4% |
| EPS (diluted) | $0.07 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $200.5M | ||
| Q4 25 | $196.9M | $201.5M | ||
| Q3 25 | $179.5M | $216.0M | ||
| Q2 25 | $181.1M | $202.8M | ||
| Q1 25 | $168.9M | $190.5M | ||
| Q4 24 | $187.3M | $192.2M | ||
| Q3 24 | $168.6M | $210.3M | ||
| Q2 24 | $178.0M | $214.2M |
| Q1 26 | $2.9M | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $5.4M | $8.6M | ||
| Q2 25 | $-4.8M | $-73.6M | ||
| Q1 25 | $4.8M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $-143.5M | $10.7M | ||
| Q2 24 | $18.9M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 79.5% | 31.5% | ||
| Q3 25 | 80.9% | 33.5% | ||
| Q2 25 | 77.4% | 31.6% | ||
| Q1 25 | 79.7% | 29.9% | ||
| Q4 24 | 78.7% | 32.1% | ||
| Q3 24 | 76.9% | 35.2% | ||
| Q2 24 | 75.1% | 34.1% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 3.5% | ||
| Q3 25 | 3.5% | 7.3% | ||
| Q2 25 | 4.7% | -33.3% | ||
| Q1 25 | 1.2% | -0.2% | ||
| Q4 24 | 13.2% | -6.6% | ||
| Q3 24 | -82.8% | 6.9% | ||
| Q2 24 | 15.9% | 5.3% |
| Q1 26 | 1.6% | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 3.0% | 4.0% | ||
| Q2 25 | -2.7% | -36.3% | ||
| Q1 25 | 2.8% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -85.1% | 5.1% | ||
| Q2 24 | 10.6% | 3.8% |
| Q1 26 | $0.07 | $0.25 | ||
| Q4 25 | $0.05 | $0.20 | ||
| Q3 25 | $0.12 | $0.48 | ||
| Q2 25 | $-0.11 | $-4.00 | ||
| Q1 25 | $0.10 | $-0.08 | ||
| Q4 24 | $0.38 | $-0.04 | ||
| Q3 24 | $-3.11 | $0.58 | ||
| Q2 24 | $0.39 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $1.2B |
| Total Assets | $1.2B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $195.8M | ||
| Q4 25 | $238.4M | $197.0M | ||
| Q3 25 | $246.3M | $167.8M | ||
| Q2 25 | $445.9M | $157.2M | ||
| Q1 25 | $493.6M | $175.6M | ||
| Q4 24 | $484.6M | $159.8M | ||
| Q3 24 | $453.8M | $146.4M | ||
| Q2 24 | $404.2M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | $1.2B | ||
| Q4 25 | $693.1M | $1.2B | ||
| Q3 25 | $727.2M | $1.2B | ||
| Q2 25 | $757.8M | $1.2B | ||
| Q1 25 | $798.5M | $1.3B | ||
| Q4 24 | $778.3M | $1.3B | ||
| Q3 24 | $749.6M | $1.3B | ||
| Q2 24 | $879.3M | $1.3B |
| Q1 26 | $1.2B | $1.4B | ||
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.6B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $5.8M |
| Free Cash FlowOCF − Capex | — | $1.1M |
| FCF MarginFCF / Revenue | — | 0.5% |
| Capex IntensityCapex / Revenue | — | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $43.7M | $46.9M | ||
| Q3 25 | $60.8M | $28.9M | ||
| Q2 25 | $12.0M | $13.7M | ||
| Q1 25 | $35.5M | $11.7M | ||
| Q4 24 | $33.1M | $33.7M | ||
| Q3 24 | $53.9M | $42.4M | ||
| Q2 24 | $53.2M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $43.5M | $42.2M | ||
| Q3 25 | $57.0M | $21.2M | ||
| Q2 25 | $9.3M | $5.6M | ||
| Q1 25 | $26.9M | $2.1M | ||
| Q4 24 | $31.0M | $18.3M | ||
| Q3 24 | $49.8M | $25.2M | ||
| Q2 24 | $51.6M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 22.1% | 20.9% | ||
| Q3 25 | 31.7% | 9.8% | ||
| Q2 25 | 5.1% | 2.8% | ||
| Q1 25 | 15.9% | 1.1% | ||
| Q4 24 | 16.6% | 9.5% | ||
| Q3 24 | 29.6% | 12.0% | ||
| Q2 24 | 29.0% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.1% | 2.3% | ||
| Q3 25 | 2.2% | 3.6% | ||
| Q2 25 | 1.5% | 4.0% | ||
| Q1 25 | 5.1% | 5.0% | ||
| Q4 24 | 1.1% | 8.0% | ||
| Q3 24 | 2.4% | 8.2% | ||
| Q2 24 | 0.9% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | 11.20× | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | 2.82× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
ROG
Segment breakdown not available.
